Debiopharm Group
Investing activity
Debiopharm Group appears in 2 AI deals tracked by the Lounge deals desk. The rounds are mostly Seed, with a median round size of $5M. The most recent are ViewsML (Seed, $4.9M, Jul 2026) and ViewsML (Seed, $4.9M, Apr 2026).
Debiopharm Group most often invests alongside Wittington Ventures, Continuum Health Ventures, Defined and RiSC Capital, and the companies it backs on Lounge are mostly in AI.
Deals
Frequently asked questions about Debiopharm Group
What AI companies has Debiopharm Group invested in?
Debiopharm Group's AI investments include ViewsML. The 2 rounds on Lounge are listed on this page with amounts, dates and co-investors.
What stage does Debiopharm Group invest at?
In the rounds tracked on Lounge, Debiopharm Group has invested at Seed, with a median round of $5M.
Who does Debiopharm Group co-invest with?
Debiopharm Group's most frequent co-investors on Lounge are Wittington Ventures (2 deals), Continuum Health Ventures (2 deals), Defined (2 deals), RiSC Capital (2 deals) and Mayo Clinic (2 deals).
How can founders reach Debiopharm Group?
Founders on Lounge can see Debiopharm Group's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add Debiopharm Group to their Investor Pipeline to track the conversation.